

美国医师执照考试


High-Yield™ *Pharmacology*

药理学

(第3版)

STEPHANIE T. WEISS

- Equips you for Step 1 pharmacology questions
- Provides a quick review of pharmacology
- Clarifies difficult concepts



北京大学医学出版社

美国医师执照考试

High-YieldTM 药理学

Pharmacology

(第3版)


Stephanie T. Weiss, PhD

Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

First and Second Editions by

Daryl Christ, PhD

Associate Professor of Pharmacology
South Bend Center for Medical Education
Indiana University School of Medicine
Notre Dame, Indiana



北京大学医学出版社

图书在版编目(CIP)数据

High-YieldTM 药理学 = High-YieldTM Pharmacology: 第3版: 英文 / (美) 韦斯 (Weiss, S.T.) 编写. —北京: 北京大学医学出版社, 2013.1
(美国医师执照考试丛书)
ISBN 978-7-5659-0477-6

I I. ①H… II. ①韦… III. ①药理学—医师—资格考试—美国—自学参考资料—英文 IV. ①R96
中国版本图书馆CIP数据核字(2012)第255518号

北京市版权局著作权合同登记号: 01-2012-5818

Stephanie T. Weiss: Pharmacology 3rd ed

ISBN: 978-0-7817-9273-8

Copyright©2009 by Lippincott Williams & Wilkins, a Wolters Kluwer business.

All Rights reserved.

This is a reprint under copublishing agreement with Lippincott Williams & Wilkins/Wolters Kluwer Health, Inc., USA

本书限在中华人民共和国境内(不包括香港、澳门特别行政区及台湾)销售。

本书封底贴有 Wolters Kluwer Health 激光防伪标签, 无标签者不得销售。

本书提供了药物的准确的适应证、副作用和疗程剂量, 但有可能发生改变。读者须阅读药商提供的外包装上的用药信息。作者、编辑、出版者或发行者对因使用本书信息所造成的错误、疏忽或任何后果不承担责任, 对出版物的内容不做明示的或隐含的保证。作者、编辑、出版者或发行者对由本书引起的任何人身伤害或财产损失不承担任何法律责任。

美国医师执照考试: High-YieldTM 药理学 (第3版)

编 写: Stephanie T. Weiss

出版发行: 北京大学医学出版社(电话: 010-82802230)

地 址: (100191)北京市海淀区学院路38号 北京大学医学部院内

网 址: <http://www.pumpress.com.cn>

E-mail: booksale@bjmu.edu.cn

印 刷: 北京京华虎彩印刷有限公司

经 销: 新华书店

责任编辑: 冯智勇 责任印制: 张京生

开 本: 787×1092mm 1/16 印张: 11.25 字数: 280千字

版 次: 2013年1月第3版 2013年1月第1次印刷

书 号: ISBN 978-7-5659-0477-6

定 价: 48.00元

版权所有, 违者必究

(凡属质量问题请与本社发行部联系退换)

出版说明

High-Yield™ 系列丛书是针对美国医师执照考试 (United States Medical Licensing Examination, USMLE) 的知名品牌图书, 受到世界各地读者的欢迎。该系列丛书具有以下特色:

1. 内容高度概括, 重点突出, 有利于读者快速掌握学科的核心知识。
2. 编排新颖, 既有基础知识要点的介绍, 又有以疾病为核心的综合归纳, 并体现了相关学科的横向联系。
3. 语言规范、地道, 既有利于读者快速掌握专业词汇, 又有利于医学英语思维的培养。

本系列丛书是参加美国医师执照考试的必备辅导用书, 也可作为我国医学院校从事双语教学的教材和参考用书, 对教师进行英语授课, 学生学习、参加考试具有重要的参考价值。

北京大学医学出版社

This book is dedicated to the spirit of the Cleveland Clinic Lerner College of Medicine.

Preface

The discipline of pharmacology encompasses both how drugs affect the body (pharmacodynamics), as well as how the body affects drugs (pharmacokinetics). Because it is such an interdisciplinary field, pharmacology necessarily is built upon a foundation consisting of nearly every other basic science discipline that is part of a medical school curriculum. You must have a good grasp of physiology, pathology, biochemistry, microbiology, and molecular biology in order to study pharmacology. Even many disciplines that people have not traditionally associated with pharmacology are turning out to be essential for understanding pharmacology, such as anatomy and genetics. In fact, one of the hottest areas in pharmacology right now is pharmacogenomics, where a patient's treatment is tailored based upon his or her unique genetic makeup.

This edition of *High-Yield Pharmacology* has been substantially updated and revised. Specifically, new sections on biologics have been added in the appropriate chapters, as well as several new figures and tables. In addition, the cardiovascular pharmacology chapter has been expanded and split in half, reflecting the rapid growth in the pharmacology of this area. Readers who desire a very brief review can read the bolded printed text, which highlights the most important concepts in each chapter. In addition, the index can be used to help you review the class of every drug in the book.

It is unfortunate that many medical students approach pharmacology as just a list of drug names and side effects that must be memorized for the United States Medical Licensing Examination. You may be using this book to review pharmacology for Step 1 of the USMLE, and I hope you will find it helpful as you prepare. But I also hope that it will give you at least an inkling of how interesting and dynamic the field of pharmacology is. Please feel free to contact me at weiss@ccf.org if you have any comments or suggestions about the book.

Stephanie T. Weiss

Acknowledgments

I would like to acknowledge the generosity of all the people whose help and support made this book possible.

My reviewers:

Lisa Potts, PharmD
Mike Militello, PharmD
Dan Sessler, MD
Kathy Franco, MD
Bill Stewart, MD
Mike Lincoff, MD
Atul Khasnis, MD
Mario Skugor, MD
Gerri Hall, PhD
Belinda Yen-Lieberman, PhD
Christopher Lowe, PharmD
Frank Peacock, MD
Pranaya Mishra, MPharm, PhD
Donald Weiss, DO

Managing Editor Kelley Squazzo and the staff at Lippincott Williams & Wilkins

The Weiss family: Alicia, Donald, Shelly, and Peanut

Contents

Preface	vii
Acknowledgments	ix

1 General Principles 1

I. Pharmacokinetics: General Principles	1
II. Pharmacokinetics: Administration and Absorption of Drugs	1
III. Pharmacokinetics: Distribution of Drugs	4
IV. Pharmacokinetics: Metabolism of Drugs	5
V. Pharmacokinetics: Elimination of Drugs and Drug Metabolites	6
VI. Pharmacodynamics	8
VII. Age-Dependent Pharmacology	11
VIII. Regulations Governing the Development of New Drugs	12

2 Peripheral Neuropharmacology 14

I. Overview of the Autonomic Nervous System	14
II. Parasympathomimetics	17
III. Cholinesterase Inhibitors	19
IV. Parasympathetic Blocking Drugs (Antimuscarinics)	20
V. Ganglionic Blocking Drugs	21
VI. Neuromuscular Blocking Drugs	22
VII. Sympathomimetics	24
VIII. α -Adrenoceptor Antagonists	26
IX. β -Adrenoceptor Antagonists	28
X. Adrenergic Neuron-Blocking Drugs	29
XI. Drugs for Glaucoma	30

3 Central Neuropharmacology 31

I. Principles of General Anesthesia	31
II. Inhalation Anesthetics	32
III. Intravenous Anesthetics	34
IV. Local Anesthetics	36
V. Sedative-Hypnotic and Antianxiety Drugs	38
VI. Anticonvulsants	40
VII. Antipsychotic Drugs (Neuroleptics)	42
VIII. Lithium Carbonate	43

IX. Antidepressants	44
X. CNS Stimulants	46
XI. Drugs for Movement Disorders	47
XII. Drugs for Alzheimer's Disease	49

4 Substance Abuse and Pain 50

I. General Features of Substance Abuse	50
II. Sedative-Hypnotics	50
III. Cigarettes	53
IV. CNS Stimulants	54
V. Anabolic Steroids	54
VI. Hallucinogens	55
VII. Marijuana	55
VIII. Gamma-Hydroxybutyric Acid (GHB)	56
IX. Opioids	56
X. Narcotic Analgesics	57
XI. Analgesic Antipyretics	59

5 Cardiovascular Pharmacology 62

I. Diuretics	62
II. Calcium Channel Blockers	64
III. Antihypertensives	65
IV. Drugs for Angina Pectoris	70
V. Drugs for Congestive Heart Failure	72
VI. Antiarrhythmics	74

6 Pharmacology of Blood and Blood Vessels 80

I. Anticoagulants	80
II. Fibrinolytics	84
III. Antiplatelet Drugs	84
IV. Antibleeding Drugs	86
V. Drugs for Anemia	86
VI. Antihyperlipidemics	87

7 Autacoids, Drugs for Inflammatory and Gastrointestinal Disorders, and Vitamins 90

I. Definition of Autacoids	90
II. Histamine	90
III. Histamine Blockers	90
IV. Antiasthmatic Drugs	91
V. Eicosanoids	93
VI. Drugs for Migraine Headaches	95
VII. Drugs for Rheumatoid Arthritis	95
VIII. Drugs for Gout	97
IX. Drugs for Acne	98
X. Vitamins	98
XI. Drugs for Gastrointestinal Disorders	99

8	Endocrine Pharmacology	102
I.	Pituitary Hormones	102
II.	Adrenocortical Steroids	104
III.	Female Sex Hormones	106
IV.	Fertility Drugs	108
V.	Male Sex Hormones	109
VI.	Thyroid Hormones	109
VII.	Calcium and Phosphate Metabolism	111
VIII.	Drugs for Diabetes Mellitus	113
IX.	Drugs for Hypoglycemia	116
X.	Drugs for Obesity	117
9	Drugs for Bacterial Infections	118
I.	Principles of Bacterial Chemotherapy	118
II.	Cell Wall Inhibitors: Penicillins	119
III.	Cell Wall Inhibitors: Cephalosporins	123
IV.	Cell Wall Inhibitors: Other β -Lactams	125
V.	Cell Wall Inhibitors: Non β -Lactams	125
VI.	Protein Synthesis (30S Ribosome) Inhibitors: Aminoglycosides and Spectinomycin	126
VII.	Protein Synthesis (30S Ribosome) Inhibitors: Tetracyclines	127
VIII.	Protein Synthesis (50S Ribosome) Inhibitors: Macrolides	128
IX.	Other Protein Synthesis (50S Ribosome) Inhibitors	128
X.	DNA Gyrase Inhibitors: Quinolones	129
XI.	Tetrahydrofolic Acid Synthesis Inhibitors	130
XII.	Miscellaneous Antimicrobials	132
XIII.	Drugs for Mycobacterial Infections	132
10	Drugs for Infections from Eukaryotic Organisms and Viruses	134
I.	Antifungal Drugs	134
II.	Antiprotozoal Drugs	136
III.	Anthelmintics	137
IV.	Antiviral Drugs	138
11	Cancer Chemotherapy	142
I.	Principles of Cancer Chemotherapy	142
II.	Anticancer Drugs	144
III.	Immunomodulators	149
12	Toxicology	152
I.	Emergency Toxicology	152
II.	Heavy Metal Toxicity and Chelators	154
III.	Other Toxic Substances	156
	Index	159

General Principles

I Pharmacokinetics: General Principles

- A. **PHARMACOKINETICS** is the study of the movement of drugs into and out of the body, including **absorption** (bioavailability), **distribution**, **metabolism** (biotransformation), and **elimination** (ADME).
- B. Clinical pharmacokinetics, which involves the **mathematical description** of the **processes of ADME**, is useful to predict the serum drug concentrations under various conditions.
- C. **PHARMACOKINETICS** can be thought of as **what the body does to the drug**.

II Pharmacokinetics: Administration and Absorption of Drugs

- A. Many routes of drug administration can be used.
 - 1. **The oral route (PO)** is usually preferred.
 - a. **Advantages** include:
 - i. **Convenience**
 - ii. A **large surface area** for absorption
 - iii. Fewer **abrupt changes of serum drug concentrations** than with parenteral administration
 - b. **Disadvantages** include:
 - i. **First-pass metabolism** by the liver
 - (a) All the blood flow from the intestinal tract goes initially to the liver through the portal vein; therefore the **drug may be metabolized before being distributed** to the other tissues in the body
 - (b) First-pass metabolism of a drug can be **avoided by parenteral administration of the drug** and partially avoided by rectal administration.
 - ii. **Systemic exposure to the drug**
 - 2. **The parenteral routes** of administration are technically more difficult and usually must be performed by a health care professional. Common methods are **inhalation**, **sublingual**, **intravenous (IV)**, **intramuscular (IM)**, and **subcutaneous (SQ) administration**.
 - a. **Advantages** include:
 - i. A **faster onset** (usually)
 - ii. **More reliable** absorption
 - iii. **No first-pass metabolism**
 - b. **Disadvantages** include:
 - i. **More difficult** administration

- ii. **Pain or necrosis** at the site of infection
 - iii. Possibility of **infection**
 - iv. **Toxicity from a bolus intravenous (IV) injection**
 - v. **Necessity of dissolving the drug if given intravenously**
- B.** Some drugs are actively or passively transported by carrier proteins, but the movement of drugs across cell membranes usually occurs passively by **diffusion**.

C. THE RATE OF DIFFUSION IS HIGH IF:

1. The unionized form of a drug has a high lipid solubility.

- a. Lipid solubility is related to the oil-water partition coefficient.
- b. Cell membranes are basically lipoidal in nature, and only lipid soluble substances will diffuse through them.

2. A large proportion of the drug is present in the unionized form.

- a. **Only the unionized form can cross cell membranes**, because the ionized form will have a very low solubility in lipids.
- b. The equilibrium between the ionized (A^-) and unionized (HA) forms of a weak acid is:




- c. The equilibrium constant (K_a) for the dissociation of an acid is defined as:

$$K_a = \frac{[A^-][H^+]}{[HA]}$$

- d. By taking the negative log ($-\log$) of both sides of the K_a expression and rearranging, we can get the Henderson–Hasselbalch equation for a weak acid:

$$pH = pK_a + \log \frac{[A^-]}{[HA]}$$

- e. The proportion of unionized drug will depend on the pH and can be determined with the Henderson–Hasselbalch equation.
- f. Weak bases also dissociate, and the equation for dissociation of the conjugate acid of a weak base is:



- g. The equilibrium constant (K_a) for the dissociation of the conjugate acid of a weak base is defined as:

$$K_a = \frac{[B][H^+]}{[HB^+]}$$

- h. By taking the negative log ($-\log$) of both sides of the K_a expression and rearranging, we can get the Henderson–Hasselbalch equation for a weak base:

$$pH = pK_a + \log \frac{[B]}{[HB^+]}$$

- i. Note that the conjugate base should always go in the numerator, while the conjugate acid belongs in the denominator.
- j. When the pH equals the pK_a , 50% of a drug will be ionized and 50% will be unionized.
- k. The most dramatic changes in the amounts of ionized and unionized drug occur with pH changes near the pK_a .